|
May 14
|
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction
|
|
May 9
|
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024
|
|
May 6
|
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript
|
|
May 3
|
Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call
|
|
May 3
|
Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 2
|
Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates
|
|
May 2
|
Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ...
|
|
May 2
|
Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
Apr 29
|
Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals
|
|
Apr 29
|
Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024
|
|
Apr 18
|
Lexicon Pharmaceuticals to Host 2024 Investor Day
|
|
Apr 16
|
All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy
|
|
Apr 3
|
Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 25
|
Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo
|
|
Mar 13
|
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
|
|
Mar 12
|
New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease
|
|
Mar 11
|
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 11
|
Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update
|
|
Mar 11
|
Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities
|
|
Mar 11
|
Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA
|